NASDAQ: KOD

Kodiak Sciences (KOD) Stock Analysis & Forecast

Nov 13 close

$111.19+2.94 (+2.7%)

Gekko Brief

AI summaryNov 9 close

Kodiak Sciences moves this week on insider and fund activity, with a Form 4 filing from Baker Bros. Advisors LP, acting as Director and 10% Owner, dated 4 November, alongside two funds, 667, L.P. and Baker Brothers Life Sciences LP, reporting purchases totaling 247,090 common shares at $98.51 per share on 4 and 5 November.

Shares close at $107.10, up 7.9%, sitting above both the 50-day average of $70.95 and the 200-day average of $44.25, with the 50-day above the 200-day. The GekkoIndex reads 48.5, placing KOD in the Neutral zone, down 2.3 over the last 5 readings. The stock trades 26.8% above Gekko Fair Value of $84.44. One-month return stands at 7.2%, three-month at 154.3%, and one-year at 533.7%, with a 52-week high of $107.53 and low of $15.83.

Earnings are due on 12 November 2026, two days away, falling inside a typical 20-trading-day holding window; the last report on 12 August showed an EPS of -1.05 against a -0.96 estimate, with a -5.1% reaction, and 3 beats across the last 8 quarters, averaging a 10.7% absolute move. Insider buying over the last 90 days totals 72 purchases worth $181.1 million. Seasonally, the next 20 trading days have averaged +26.9% across 5 years, rising in 4 of them. Analyst consensus from 7 firms carries 6 buy ratings, 1 hold, and a $121.67 target.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Kodiak Sciences price vs fair value

$111.19$88.14Nov ’25May ’26Nov ’26
Close $111.19200-day averageGekko Fair Value $88.14

Kodiak Sciences quick facts

Market cap
$6.99B
P/E ratio
—
Forward P/E
—
EPS, TTM
−$4.19
Revenue, TTM
$0
Profit margin
0%
Dividend yield
—
Beta
1.98
Volume
970,567 avg 854,561
1-year return
+449.1%
Typical daily move
±5.8%
Typical 20-day move
±19.4%
50-day average
$76.72
200-day average
$45.93
Next earnings
—
Shares outstanding
62.85M
52-week range
$18.05$112.79

Kodiak Sciences swing-trade checklist

Kodiak Sciences scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive1 mixed1 headwind

  • Trendsupportive

    Above 50 and 200-day

    Close $111.19 is above the 50-day ($76.72) and 200-day ($45.93) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    47.6, Neutral

    Reading 47.6 is in the Neutral zone.

    See the GekkoIndex
  • Fair valueheadwind

    26.2% above

    Price is 26.2% above Gekko Fair Value (more than 5% above).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 90 days: 72 open-market insider purchases.

    See smart money
  • Earnings riskno data

    No data

    No confirmed report date on the calendar.

    See earnings
  • Seasonalitysupportive

    +19.9% on average

    From this point in the calendar, the next 20 trading days averaged +19.9% over 5 years, rising in 4 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Kodiak Sciences stock chart and price history

Kodiak Sciences closed at $111.19 on Nov 13, 2026, +449.1% over the past year, inside a 52-week range of $18.05 to $112.79.

Close50-day average200-day averageVolume
Kodiak Sciences share price, past year, with 50-day and 200-day moving averages and volume$20$40$60$80$100DecJan 2026FebMarAprMayJunJulAugSepOctNov111.19

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+26.2%
3 months
+171.3%
6 months
+200.4%
1 year
+449.1%
The full KOD chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open KOD in Gekko

Follow Kodiak Sciences through every session

Put KOD on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track KOD in GekkoFree for 7 days. No credit card required.

About Kodiak Sciences

Kodiak Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for diseases of the retina. Its lead program, KSI-301, is an antibody biopolymer designed to inhibit anti-VEGF activity and is being studied in Phase IIb/III trials for conditions including wet age-related macular degeneration, diabetic macular edema, macular edema linked to retinal vein occlusion, and non-proliferative diabetic retinopathy.

Beyond its lead candidate, Kodiak Sciences maintains an earlier-stage pipeline aimed at other retinal disorders. This includes KSI-501, a bispecific conjugate intended for retinal conditions marked by inflammation, and KSI-601, a triplet inhibitor being explored as a potential approach to dry age-related macular degeneration. These programs remain in preclinical stages of development.

The company traces its origins to 2009, when it was founded as Oligasis, LLC, later adopting the Kodiak Sciences name in September 2015. It is headquartered in Palo Alto, California. Shares of Kodiak Sciences trade on the NASDAQ under the ticker KOD.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
kodiak.com

Kodiak Sciences GekkoIndex: the smart money zone

Kodiak Sciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 47.6, in the Neutral zone, down 3.6 points over five sessions.

010047.6Neutral

Down 3.6 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying45+8.9%+33.7%+40.1%+10.5%
Accumulation194+4.8%+5.7%+14.0%+25.1%
Neutral (current zone)381+3.2%+5.7%+11.5%+48.7%
Distribution70+5.7%+12.1%+30.8%+37.3%
Selling12Not available

Average KOD share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the KOD price, zone by zone.Track KOD in Gekko

Is Kodiak Sciences stock overvalued? Gekko Fair Value

Kodiak Sciences trades 26.2% above Gekko Fair Value of $88.14, so the shares are overvalued on Gekko’s estimate.

Gekko’s own estimate of what Kodiak Sciences shares are worth, recalculated every trading day.

$88.14

Gekko Fair Value, Nov 14, 2026

26.2% Overvalued

At the end of Aug 2026 the price was 37.0% below the estimate.

Gekko Fair ValueShare price, month end
$88$111Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open KOD in Gekko

Kodiak Sciences insider and Congress trading

Insiders filed 72 open-market purchases in Kodiak Sciences worth $181.1M, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

$181.1Min 72 open-market purchases

FiledInsiderTypeSharesValue
Nov 6BAKER BROS. ADVISORS LP
director, 10 percent owner:
Purchase151,916$14.97M
Nov 6BAKER BROS. ADVISORS LP
director, 10 percent owner:
Purchase81,729$8.05M
Nov 6BAKER BROS. ADVISORS LP
director, 10 percent owner:
Purchase8,742$861K
Nov 6BAKER BROS. ADVISORS LP
director, 10 percent owner:
Purchase4,703$463K
Sep 30BAKER BROS. ADVISORS LP
director, 10 percent owner:
Purchase278,978$20.19M

From Form 4 filings, dated to when each was filed.

Congress trades last 90 days

No trades in KOD were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for KOD, plotted on the chart in Gekko.Open KOD in Gekko

Buybacks

Kodiak Sciences has been buying back its own shares.

Bought back, year ended Dec 31, 2020
$487K
As a share of market cap
0.01%

From company filings.

Kodiak Sciences earnings: next date and track record

Kodiak Sciences beat the EPS estimate in 3 of its last 8 reports, moving 10.7% on average across the report.

3 of 8reports beat the EPS estimate
±10.7%average move across the report
3 of 8reports followed by a gain

Share-price move across each report

+0.5%Nov ’24−3.3%Mar ’25−17.4%May ’25+17.8%Aug ’25−3.7%Nov ’25+27.2%Mar ’26−10.6%May ’26−5.1%Aug ’26
ReportedEPSSurpriseRevenueSurpriseMove
Aug 12, 2026−$1.05
est −$0.96
−9.8%——−5.1%
May 7, 2026−$1.04
est −$0.70
−48.9%——−10.6%
Mar 31, 2026−$1.04
est −$1.01
−3.0%——+27.2%
Nov 13, 2025−$1.16
est −$1.07
−8.4%——−3.7%
Aug 13, 2025−$1.03
est −$1.04
+1.0%——+17.8%
May 14, 2025−$1.09
est −$0.87
−24.7%——−17.4%
Mar 27, 2025−$0.84
est −$0.86
+2.8%——−3.3%
Nov 14, 2024−$0.84
est −$0.90
+6.7%——+0.5%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Kodiak Sciences stock forecast and analyst price targets

Analysts’ average 12-month price target for Kodiak Sciences is $121.67, +9.4% from the last close, from 7 firms rating the stock in the last 90 days.

$121.67consensus 12-month target, +9.4% from the last close
Low $103High $150
Buy6
Hold1
Sell0

Each firm’s latest rating in the last 90 days: 7 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 13UBSBuy, reiterated$150+34.9%
Oct 12H.C. WainwrightBuy, reiterated$126+13.3%
Oct 5JefferiesBuy, maintained$112+0.7%
Sep 29Goldman SachsHold, maintained$103−7.4%
Sep 29H.C. WainwrightBuy, reiterated$96−13.7%
+11.5%average 20-day move after past Neutral readings
+19.9%average move over the next 20 trading days in the last 5 years
±5.8%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Kodiak Sciences seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Kodiak Sciences averaged +19.9% across the last 5 years, rising in 4 of them.

Next 20 trading days, by year

−22.0%2021+0.4%2022+51.0%2023+59.8%2024+18.0%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+5.1%4 of 5
Next 10 trading days+9.5%3 of 5
Next 15 trading days+22.8%4 of 5
Next 20 trading days+19.9%4 of 5
Next 30 trading days+33.6%3 of 5

For scale, KOD’s typical 20-trading-day move in either direction is about 19.4%.

Kodiak Sciences market cap and key statistics

Kodiak Sciences’s market cap is $6.99B and revenue of $0 over the last twelve months.

Valuation

Market cap
$6.99B
EPS, TTM
−$4.19
Gekko Fair Value
$88.14

Trading

Volume
970,567
Avg volume, 20 days
854,561
52-week high
$112.79
52-week low
$18.05
Shares outstanding
62.85M

Financials

Revenue, TTM
$0
Profit margin
0%
Return on equity
-368.4%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
1.98
Typical daily move
±5.8%
Typical 20-day move
±19.4%

Kodiak Sciences peers

Kodiak Sciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

Kodiak Sciences stock FAQ

What is Kodiak Sciences’s market cap?

Kodiak Sciences’s market cap is $6.99B at the Nov 13, 2026 close of $111.19, with 62.85M shares outstanding.

What is the Kodiak Sciences stock forecast?

The consensus analyst 12-month price target for Kodiak Sciences is $121.67, +9.4% from the last close. Of the 7 firms that rated the stock in the last 90 days, 6 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Kodiak Sciences stock overvalued or undervalued?

On Gekko’s estimate Kodiak Sciences is overvalued: the Nov 13, 2026 close of $111.19 is 26.2% above Gekko Fair Value of $88.14. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

What is Kodiak Sciences’s 52-week high and low?

Kodiak Sciences’s 52-week high is $112.79 and its 52-week low is $18.05; it closed at $111.19 on Nov 13, 2026, +449.1% over the past year.

Is Kodiak Sciences stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, smart money and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Kodiak Sciences the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.